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Abstract
Background: The down-regulation of E-cadherin gene (CDH1) expression has been regarded as an important
event in cancer invasion and metastasis. However, the association between CDH1 promoter methylation and
ovarian cancer remains unclear. A meta-analysis was conducted to evaluate the potential role of CDH1 promoter
methylation in ovarian cancer.
Methods: Relevant articles were identified by searches of PubMed, EMBASE, Cochrane Library, CNKI and Wanfang
databases. The pooled odds ratio (OR) and corresponding 95 % confidence interval (CI) were calculated to assess
the strength of association.
Results: Nine studies were performed using the fixed-effects model in this study, including 485 cancer tissues and 255
nonmalignant tissues. The findings showed that CDH1 promoter methylation had an increased risk of ovarian cancer in
cancer tissues (OR = 8.71, P < 0.001) in comparison with nonmalignant tissues. Subgroup analysis of the ethnicity showed
that the OR value of CDH1 methylation in Asian population subgroup (OR = 13.20, P < 0.001) was higher than that in
Caucasian population subgroup (OR = 3.84, P = 0.005). No significant association was found between ovarian cancer and
low malignant potential (LMP) tumor (P = 0.096) among 2 studies, and between CDH1 promoter methylation and tumor
stage and tumor histology (all P > 0.05). There was not any evidence of publication bias by Egger’s test (all P > 0.05).
Conclusions: CDH1 promoter methylation can be a potential biomarker in ovarian cancer risk prediction, especially
Asians can be more susceptible to CDH1 methylation. However, more studies are still done in the future.
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Background
Ovarian cancer, the most lethal tumor in gynecologic can-
cers, is the fifth most cause of cancer-related deaths among
women. According to cancer statistics, approximately
21,290 women will be diagnosed and 14,180 will die due to
ovarian cancer in the United States in 2015 [1]. Among
ovarian cancer, serous ovarian carcinoma is the most com-
mon histotype and only less than 20 % of ovarian cancer
can be detected early due to the lack of effective early
detection and accurate diagnosis methods [2]. More than
80 % of ovarian cancer patients at advanced stages relapse
[3]. While the overall 5-year survival rate is only 31 % [4].
Epigenetic alterations (DNA methylation, histone modifi-
cations, nucleosome positioning and non-coding RNAs)
are identified to be strongly associated with cancer [5].
DNA methylation is an important mechanism of epigenetic
variability involved in gene expression, which plays key
roles in the development of cancer [6–8]. Aberrant methy-
lation of CpG islands of the promoter regions is the major
alternative to accomplish tumor suppressor gene (TSG)
silencing [9–11]. CDH1, a tumor suppressor gene, also
called as epithelial cadherin (E-cadherin) and cadherin-1, is
located on 16q23 [12]. CDH1, a member of the cadherin
family, plays an important role in epithelial cell-cell adhe-
sion and in maintaining normal tissue architecture [13].
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The reduction of CDH1 expression may involve in invasion
and metastasis of several cancers [13–15].
However, the association between CDH1 promoter
methylation and ovarian cancer remains to be certified.
In this study, we performed a meta-analysis to evaluate
the relationships between ovarian cancer tissues and
nonmalignant ovarian tissues and Low malignant poten-
tial (LMP) tumor tissues. In addition, we also assess the
relationship between CDH1 promoter methylation and
clinicopathological features in ovarian cancer.
Methods
Literature search and selection criteria
A systematic literature search was performed in PubMed,
EMBASE, Cochrane Library, CNKI and Wanfang data-
bases, using the following keywords and search items:
(CDH1 OR E-cadherin OR cadherin 1) AND (ovarian OR
ovary) AND (cancer OR carcinoma OR tumor) AND
methylation. The search updated until December 25. 2015.
Moreover, a manual search of the references was also con-
ducted to identify the potentially additional articles.
For eligible studies, studies must meet the following cri-
teria: (1) all patients were diagnosed for primary ovarian
cancer; (2) the study was about CDH1 promoter methyla-
tion and ovarian cancer; (3) study must have sufficient data
about the frequencies of CDH1 promoter methylation to
assess to the relationship between CDH1 promoter methy-
lation and ovarian cancer; (4) only the most recent paper or
the most complete one was selected to avoid duplicated
publications. Study was excluded if it did not meet the
inclusion criteria above.
Data extraction
For each eligible study, the following information were ex-
tracted: the first author’s name, publication year, methyla-
tion region, country, ethnicity, the method of methylation
detection, type of control, the number of methylation, the
sample size, clinicopathological parameters, such as the
number of tumor stage, the number of tumor histology,
etc. Nonmalignant ovarian tissues were defined as con-
trols, including benign disease, normal tissues or adjacent
normal tissues. Low malignant potential (LMP) tumors
were also served as a single control group.
Statistical analysis
Meta-analysis was conducted using the STATA software
(version 12.0, Stata Corporation, College Station, TX,
USA). The pooled odds ratios (OR) and 95 % confidence
interval (95 % CI) were calculated to evaluate the associ-
ation between CDH1 promoter methylation and ovarian
cancer risk. Between-study heterogeneity was examined
using the Cochran’s Q test and I2 statistic [16]. If I2 < 50 %
and p ≥ 0.1 were considered as a measure of lack hetero-
geneity, a fixed-effects model was applied; otherwise, the
random-effects model was used [17, 18]. Publication bias
was assessed by using Egger’s linear regression test [19].
Results
Study characteristics
One hundred twenty-seven potentially relevant articles
were initially identified by the databases above. These
studies were further selected based on the inclusion cri-
teria. Finally, a total of 9 studies met the inclusion criteria
were included in the current meta-analysis (Fig. 1). The
methylation region of these studies was promoter. Among
these studies, 8 studies used methylation-specific polymer-
ase chain reaction (MSP) and 1 study used methylation
specific headloop suppression PCR (MSHSP). There were
two control groups, including nonmalignant control with
8 studies and LMP control with 2 studies. 8 studies evalu-
ated the association between CDH1 promoter methylation
and ovarian cancer risk, 4 studies evaluated the relation-
ship between CDH1 and tumor histology, and 3 studies
assessed the relationship between CDH1 and tumor stage.
The main characteristics of included studies were listed in
Table 1 [20–26].
The association between CDH1 promoter methylation and
OC risk
Significant between-study heterogeneity was not detected
(I2 = 16.6 % and P = 0.299), a fixed-effects model was used.
A significant association was observed between CDH1
promoter methylation and ovarian cancer among 8 studies
(OR = 8.71, 95 % CI = 4.87 - 15.58, P < 0.001), including
435 malignant tissues from ovarian cancer and 255
nonmalignant tissues (Fig. 2). Subgroup analysis based on
the ethnic population showed that the CDH1 promoter
methylation status was significant associated with the risk
of ovarian cancer in Asian population and Caucasian
population (OR = 13.20, 95 % CI = 6.12 - 28.45, P < 0.001;
OR = 3.84, 95 % CI = 1.52 - 9.74, P = 0.005; respectively)
(Fig. 3). No significant association was found in the com-
parison of ovarian cancer and LMP tumor (OR = 2.40,
95 % CI = 0.86 - 6.76, P = 0.096), reporting a total of 109
ovarian cancer patients and 37 low malignant tumor
patients in 2 studies (Table 2).
The association of CDH1 promoter methylation and
clinicopathological features
The associations between CDH1 promoter methylation
and clinicopathological features were further analyzed in
the present meta-analysis (Table 2), such as tumor stage
(57 early ovarian cancer patients vs. 142 advanced ovarian
cancer patients) and tumor histology (122 serous cancer
patients vs. 82 non-serous cancer patients), including 3
studies and 4 studies respectively. Between-study hetero-
geneity was lack (P > 0.1), the fixed-effects model was
used. The result showed that CDH1 promoter methylation
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Table 1 The main characteristics of included studies in this meta-analysis
First author Region Country Race Method Sample Control Case Control Stage 1-2 Stage 3-4 Serous Non-serous
M/N M/N M/N M/N M/N M/N
Rathi 2002 [35] Promoter USA Caucasians MSP Tissue NMT 14/
49
2/39 - - - -
Makarla 2005 [21] Promoter USA Caucasians MSP Tissue NMT 6/23 4/39 - - 2/9 3/13
Makarla 2005 [21] Promoter USA Caucasians MSP Tissue LMP 6/23 4/23 - - - -
Yuecheng 2006 [26] Promoter China Asians MSP Tissue NMT 34/
80
0/34 - - - -
Shen 2007 [23] Promoter China Asians MSP Tissue NMT 18/
63
1/30 2/22 16/41 9/34 9/29
Montavon 2012 [34] Promoter Australia Caucasians MSHSP Tissue NMT 17/
78
1/5 - - - -
Bhagat 2013 [20] Promoter India Asians MSP Tissue NM 31/
86
2/34 8/23 23/63 17/44 7/25
Bhagat 2013 [20] Promoter India Asians MSP Tissue LMP 31/
86
2/14 - - - -
Wu 2014 [25] Promoter China Asians MSP Tissue NMT 32/
50
- 7/12 25/38 25/35 7/15
Moselhy 2015 [22] Promoter Saudi
Arabia
Asians MSP Tissue NMT 12/
18
8/32 - - - -
Sun and Zhang 2015
[24]
Promoter China Asians MSP Tissue NMT 15/
38
1/42 - - - -
MSP Methylation Specific PCR, MSHSP Methylation specific headloop suppression PCR, NMT nonmalignant tissues, LMP low malignant potential tumor, “-” indicates
data not available, M stands for the number of methylation positive, N stands for the number of the total samples
Fig. 1 Flow diagram of the literature search strategy
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was not significantly associated with tumor histology and
tumor stage (OR = 1.41, 95 % CI = 0.76 - 2.60, P = 0.273;
OR = 0.55, 95 % CI = 0.28 - 1.08, P = 0.082; respectively).
Publication bias
Egger’s test was performed to estimate the publication bias
of included studies. Egger’s test of CDH1 methylation of
cancer versus nonmalignant control showed that there was
not any evidence of publication bias (P = 0.335). No publi-
cation bias was detected in tumor histology and tumor
stage (P = 0.935 and P = 0.316 respectively) (Table 2).
Discussion
The gene epigenomic regulation of initiation and pro-
gression of cancer has two essential components of the
molecular mechanism, which are the hypermethylation
of tumor suppressor genes and hypomethylation of
oncogenes [27–29]. The CpG islands methylation of the
promoter is an important reason for loss of gene expres-
sion, which can lead to the transcription repression of the
gene [30]. Inactivation of CDH1 by promoter hypermethy-
lation has been observed in several types of cancers,
including breast cancer, ovarian cancer and gastric cancer
[31–33]. However, the frequency of CDH1 promoter
methylation was inconsistent. Montavon et al. reported
that the frequency of CDH1 promoter methylation was
21.8 % and 20 % in ovarian cancer and nonmalignant
ovarian disease respectively [34]. Rathi et al. reported that
the frequency of CDH1 promoter methylation was 28.6 %
and 5 % in ovarian cancer tissues and nonmalignant
tissues respectively [35]. So the current meta-analysis was
performed to identify the association between CDH1 pro-
moter methylation and ovarian cancer risk.
A total of 9 studies including 485 cancer tissues and 255
nonmalignant tissues were involved in our study. CDH1
promoter methylation had an increased risk in cancer
tissues (OR = 8.71, 95 % CI = 4.87 - 15.58, P < 0.001) in
comparison with nonmalignant tissues. Subgroup analysis
based on the ethnicity suggested that the CDH1 promoter
methylation status was significantly increased risks of ovar-
ian cancer in Asian population and Caucasian popula-
tion (OR = 13.20, 95 % CI = 6.12 - 28.45; OR = 3.84,
95 % CI = 1.52 - 9.74; respectively). The OR value of
Asian population subgroup (OR = 13.20) was higher than
that in Caucasian population subgroup (OR = 3.84), sug-
gesting that Asian population can be more susceptible to
Fig. 2 Forest plot of the association between CDH1 promoter methylation and ovarian cancer
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Fig. 3 Forest plot of the association between CDH1 promoter methylation and ovarian cancer based on subgroup analysis of the ethnicity
Table 2 Summary of the association of CDH1 promoter methylation and ovarian cancer
Studies Overall OR 95CI % I2; p P value Cases Controls p (Egger’s test)
NMT group 8 8.71(4.87 - 15.58) 16.6 %; 0.299 <0.001 435 255 0.335
Race
Asians 5 13.20 (6.12 - 28.45) 0.0 %; 0.545 <0.001 285 172
Caucasians 3 3.84 (1.52 - 9.74) 0.0 %; 0.380 0.005 150 83




Histology Stage 1-2 Stage 3-4
4 1.41 (0.76 - 2.60) 0.0 %; 0.483 0.273 122 82 0.935
Patients
Stage Serous Non-serous
3 0.55 (0.28 - 1.08) 45.3 %; 0.161 0.082 57 142 0.316
NMT nonmalignant tissues, LMP low malignant potential tumor
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CDH1 promoter methylation. However, the results should
be interpreted with caution as only small subjects were
included in subgroup analyses. No significant associ-
ation was observed between ovarian cancer and LMP
tumor (P = 0.096), including a total of 109 ovarian can-
cer patients and 37 low malignant tumor patients.
We further evaluated the relationships of CDH1 pro-
moter methylation with clinicopathological features, such
as tumor histology and tumor stage. Our findings indicated
that the CDH1 promoter methylation status was not signifi-
cantly associated with tumor stage and histology. Publica-
tion bias was not detected by Egger’s test (all P > 0.05).
The current study had some limitations. Firstly, the
search strategy was restricted to articles published in
English or Chinese. Secondly, the total sample size was
not sufficient larger (less than 1000) [36], our results may
be lack vigorous power to evaluate the associations be-
tween CDH1 promoter methylation and ovarian cancer
risk. Thirdly, based on the limitation of insufficient data,
we did not study the CDH1 promoter methylation status
in other clinicopathological features, such as tumor grade,
sex status and age etc. Therefore, a meta-analysis includ-
ing more studies with larger sample size should be neces-
sary to confirm the results in the future.
Conclusion
CDH1 promoter methylation is significantly associated
with ovarian cancer risk. In addition, the potential associ-
ation on CDH1 promoter methylation and some clinico-
pathological features are still unclear due to the limitation
of studies and sample size.
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